HCN Downgraded On Valuation
Analysts at RW Baird downgrade Health Care (NYSE: HCN) from "neutral" to "underperform." The target price for HCN is set to $42.
According to RW Baird, the downgrade in rating is based on valuation, which is not justified by the near term fundamentals.
HCN’s shares gained 0.50% to close at $46.21 yesterday. More Analyst Ratings here
(c) 2011 Benzinga.com. All rights reserved. This material may not be published in its entirety or redistributed without the approval of Benzinga.
We're Loving
